Emyria Ltd
AASX:EMD0.04
AUD
+0.00
(+7.32%)
ISIN
AU0000073645
Return %
Stock
S&P 500
1Y
-32.31
14.20
3Y
-29.03
81.12
5Y
-81.02
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Gregory Hutchinson
- Full Time Employees
- 6
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Level 1, 516 Hay Street Leederville WA Australia 6008
- IPO Date
- Feb 12, 2020
- Website
- emyria.com
- Similar Companies
- Business
- Emyria Limited (ASX:EMD) is an Australia-based clinical-stage drug development and healthcare services company focused on mental health and neurological conditions; it operates specialist clinics delivering evidence-based treatments including psychedelic-assisted therapies for PTSD and treatment-resistant depression, alongside a biopharmaceutical pipeline featuring MDMA analogues, ultra-pure cannabidiol (CBD) capsules such as EMD-RX5 and high-potency variants, and novel serotonin-releasing agents; through subsidiaries like Emyria Healthcare and Emerald Clinics, it provides medication-assisted programs and gathers real-world patient data via proprietary software to inform drug development and therapy optimization. Founded in 2018 and headquartered in Leederville, Western Australia, the company targets patients unresponsive to conventional care across Australia, with plans for national expansion including Empax Centres. Recent developments include the 2023 acquisition of Pax Centre, a leading psychological trauma care provider, for A$1.7 million to bolster psychedelic therapy capabilities; a November 2024 capital raise of A$2.525 million to fund clinic growth and the treatment-resistant depression program; an exclusive partnership with the University of Western Australia signed in October 2024 for commercializing serotonin-releasing agents supported by a WA government grant; alliances with Medibank for funded PTSD treatments, Avive Health for a Brisbane Empax clinic launch, and Cann Group for S3 medicine CBD registration; plus Perth clinic expansion amid rising demand and ethics approvals for MDMA, ketamine, and psilocybin therapies.